Philip G Murray

List of Publications by Year in Descending Order

24 papers	1,067 citations	14 h-index	25 g-index
25 ext. papers	1,298 ext. citations	6.9 avg, IF	3.95 L-index

#	Paper	IF	Citations
24	Role of Genotype and Expression in Growth and Response to Recombinant Human Growth Hormone Treatment.. *Journal of the Endocrine Society*, **2022**, 6, bvac006	0.4	0
23	Pharmacogenomics applied to recombinant human growth hormone responses in children with short stature. *Reviews in Endocrine and Metabolic Disorders*, **2021**, 22, 135-143	10.5	3
22	Gene expression signatures predict response to therapy with growth hormone. *Pharmacogenomics Journal*, **2021**, 21, 594-607	3.5	0
21	Recommendations for Diagnosis and Treatment of Pseudohypoparathyroidism and Related Disorders: An Updated Practical Tool for Physicians and Patients. *Hormone Research in Paediatrics*, **2020**, 93, 182-196	3.3	16
20	The in vitro functional analysis of single-nucleotide polymorphisms associated with growth hormone (GH) response in children with GH deficiency. *Pharmacogenomics Journal*, **2019**, 19, 200-210	3.5	2
19	A genetic approach to evaluation of short stature of undetermined cause. *Lancet Diabetes and Endocrinology,the*, **2018**, 6, 564-574	18.1	28
18	Transcriptomics and machine learning predict diagnosis and severity of growth hormone deficiency. *JCI Insight*, **2018**, 3,	9.9	8
17	Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement. *Nature Reviews Endocrinology*, **2018**, 14, 476-500	15.2	132
16	Diagnosis and management of Silver-Russell syndrome: first international consensus statement. *Nature Reviews Endocrinology*, **2017**, 13, 105-124	15.2	224
15	Validating genetic markers of response to recombinant human growth hormone in children with growth hormone deficiency and Turner syndrome: the PREDICT validation study. *European Journal of Endocrinology*, **2016**, 175, 633-643	6.5	11
14	A recurrent mitochondrial p.Trp22Arg NDUFB3 variant causes a distinctive facial appearance, short stature and a mild biochemical and clinical phenotype. *Journal of Medical Genetics*, **2016**, 53, 634-41	5.8	20
13	Metabolites involved in glycolysis and amino acid metabolism are altered in short children born small for gestational age. *Pediatric Research*, **2016**, 80, 299-305	3.2	5
12	Identifying biological pathways that underlie primordial short stature using network analysis. *Journal of Molecular Endocrinology*, **2014**, 52, 333-44	4.5	22
11	How to assess tall stature. *Paediatrics and Child Health (United Kingdom)*, **2013**, 23, 409-413	0.6	0
10	Endocrine control of growth. *American Journal of Medical Genetics, Part C: Seminars in Medical Genetics*, **2013**, 163C, 76-85	3.1	68
9	Pediatric perspective on pharmacogenomics. *Pharmacogenomics*, **2013**, 14, 1889-905	2.6	15
8	Exploring the spectrum of 3-M syndrome, a primordial short stature disorder of disrupted ubiquitination. *Clinical Endocrinology*, **2012**, 77, 335-42	3.4	44

7	The genetics of 3-M syndrome: unravelling a potential new regulatory growth pathway. *Hormone Research in Paediatrics*, **2011**, 76, 369-78	3.3	33
6	Exome sequencing identifies CCDC8 mutations in 3-M syndrome, suggesting that CCDC8 contributes in a pathway with CUL7 and OBSL1 to control human growth. *American Journal of Human Genetics*, **2011**, 89, 148-53	11	85
5	Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. *Nature Reviews Endocrinology*, **2011**, 7, 11-24	15.2	241
4	The primordial growth disorder 3-M syndrome connects ubiquitination to the cytoskeletal adaptor OBSL1. *American Journal of Human Genetics*, **2009**, 84, 801-6	11	83
3	Use of nasal continuous positive airway pressure during retrieval of neonates with acute respiratory distress. *Pediatrics*, **2008**, 121, e754-8	7.4	25
2	Growth hormone, the insulin-like growth factor axis, insulin and cancer risk		1
1	Gene expression signatures predict response to therapy with growth hormone		1